Lymphocyte Subpopulations, Oxidative Burst and Apoptosis in Peripheral Blood Cells of Patients with Multiple Sclerosis–Effect of Interferon-β

References

• Adorini, L. (2001) "Selective immunointervention in autoimmune diseases: lessons from multiple sclerosis", J. Chemother. 13, 219–234.
   PubMed Web of Science ®Google Scholar
• Jacobs, L.D., Beck, R.W., Simon, J.H., Kinkel, R.P., Brownscheidle, CM., Murray, T.J., Simonian, N.A., Slasor, P.J. and Sandrock, A.W. CHAMPS Study Group. (2000) "Intramuscular interferon 13-la therapy initiated during a first demyelinating event in multiple sclerosis", N. Engl. J. Med. 343, 898–904.
   PubMedGoogle Scholar
• Durelli, L., Ferrero, B., Grezzi, A., Montanan, E., Zaffaroni, M., Bergui, M., Verdun, E. and Barbero, P. The INCO1VIIN Trial Study Group. (2001) "The independent comparison of interferon (INCO1VIIN) trial: A multicenter randomized trial comparing clinical and MRI efficacy of IFN13-1 a and a-lb in multiple sclerosis. INCOMIN Study Group (Abstract)", Neurology 56\(Suppl. 3), A148.
   PubMedGoogle Scholar
• Brod, S.A., Nelson, L.D., Khan, M. and Wolinsky, J.S. (1997) "IFN-13 lb treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months", Int. J. Neurosci. 90, 135–144.
   PubMed Web of Science ®Google Scholar
• özenci, V., Kouwenhoven, M., Teleshova, N., Pashenkov, M., Fredrikson, S. and Link, H. (2000) "Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-13", J. Neuroimmunol. 108, 236–243.
   PubMed Web of Science ®Google Scholar
• Karp, CL., van Boxel-Dezaire, A.H.H., Byrnes, A.A. and Nagelkerken, L. (2001) "Interferon-13 in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10?", Curr. Opin. Neurol. 14, 361–368.
   Google Scholar
• Genc, K., Dona, D.L. and Reder, A.T. (1997) "Increased CD80+ B cells in active multiple sclerosis and reversal by interferon 13-lb therapy", J. Clin. Investig. 99, 2664–2671.
   PubMed Web of Science ®Google Scholar
• Yong, V.W., Chabot, S., Stiive, 0. and Williams, G. (1998) "Interferon 13 in the treatment of multiple sclerosis. Mechanisms of action", Neurology 51, 682–689.
   PubMed Web of Science ®Google Scholar
• Soilu-Hänninen, M., Salmi, A. and Salonen, R. (1995) "Interferon-13 downregulates expression of VLA-4 antigen and antagonizes interferon--y-induced expression of HLA-DQ on human peripheral blood monocytes", J. Neuroimmunol. 60, 99–106.
   PubMed Web of Science ®Google Scholar
• Jiang, H., Williams, G.J. and Dhib-Jalbut, S. (1997) "The effect of interferon 13-lb on cytokine-induced adhesion molecule expression", Neurochem. Int. 30, 449–453.
   PubMedGoogle Scholar
• Nguyen, L.T., Ramanathan, M., Munschauer, F., Brownscheidle, C., Krantz, S., Umhauer, M., Miller, C., DeNardin, E. and Jacobs, L.D. (1999) "Flow cytometric analysis of in vitro proinflammatory cytokine secretion in peripheral blood from multiple sclerosis patients", Clin. Immunol. 19, 179–185.
   Google Scholar
• Kallmann, BA., Hummel, V., Lindenlaub, T., Ruprecht, K., Toyka, K.V. and Rieckmann, P. (2000) "Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1", Brain 123, 687–697.
   PubMed Web of Science ®Google Scholar
• Liu, Z., Pelfrey, CM., Cotleur, A., Lee, J.C. and Rudick, R.A. (2001) "Immunomodulatory effects of interferon 13-la in multiple sclerosis", J. Neuroimmunol. 112, 153–162.
   PubMed Web of Science ®Google Scholar
• Wandinger, KR, Stiirzebecher, CS., Bielekova, B., Detore, G., Rosenwald, A., Staudt, L.M., McFarland, H.F. and Martin, R. (2001) "Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes", Ann. Neurol. 50, 349–357.
   PubMed Web of Science ®Google Scholar
• Sorensen, T.L., Roed, H. and Sellebjerg, F. (2002) "Chemokine receptor expression on B cells and effect of interferon-13 in multiple sclerosis", J. Neuroimmunol. 122, 125–131
   PubMedGoogle Scholar
• Stiive, 0., Dooley, NY., Uhm, J.H., Antel, J.P., Francis, G.S., Williams, G. and Yong, V.W. (1996) "Interferon 13-lb decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9", Ann. Neurol. 40, 853–863.
   PubMedGoogle Scholar
• Zettl, U.K., Mix, E., Zielasek, J., Stangel, M., Hartung, R-P. and Gold, R. (1997) "Apoptosis of myelin-reactive T cells induced by reactive oxygen and nitrogen intermediates in vitro", Cell Immunol. 178, 1–8.
   PubMedGoogle Scholar
• Hua, L.L., Liu, J.S., Brosnan, C.F. and Lee, S.C. (1998) "Selective inhibition of human glial inducible nitric oxide synthase by interferon-13: implications for multiple sclerosis", Ann. Neurol. 43, 384–387.
   PubMedGoogle Scholar
• Alcazar, A., Regidor, I., Masjuan, J., Salinas, M. and Alvarez-Cermeno, J.C. (1998) "Induction of apoptosis by cerebrospinal fluid from patients with primary-progressive multiple sclerosis in cultured neurons", Neurosci. Lett. 16, 75–78.
   Google Scholar
• Rep, M.H., Schrijver, H.M., van Lopik, T., Hintzen, R.Q., Roos, MT., Ader, H.J., Polman, C.H. and van Lier, R.A. (1999) "Interferon (IFN)-13 treatment enhances CD95 and interleukin 10 expression but reduces interferon-13 producing T cells in MS patients", J. Neuroimmunol. 96, 92–100.
   PubMed Web of Science ®Google Scholar
• Correale, J., Mix, E., Olsson, T., Kostulas, V., Fredrikson, S., Höjeberg, B. and Link, H. (1991) "CD5+ B cells and CD4-8- T cells in neuroimmunological diseases", J. Neuroimmunol. 92, 123–132.
   Google Scholar
• Selmaji, K., Brosnan, C.F. and Raine, C.S. (1991) "Colocalization of lymphocytes bearing 'ya T-cell receptor and hsp 65+ oligodendrocytes in multiple sclerosis", Proc. Natl Acad. Sci. USA 88, 6452–6456.
   PubMedGoogle Scholar
• Mix, E., Fiszer, U., Olsson, T., Fredrikson, S., Kostulas, V., Söderström, M. and Link, H. (1994) "Va 1 gene usage, interleukin-2 receptors, and adhesion molecules on 'N/8+ T cells in inflammatory diseases of the nervous system", J. Neuroimmunol. 49, 59–66.
   PubMedGoogle Scholar
• Scott, T.F., McKolanis, J., Rothfus, W. and Cottington, E. (1994) "Lymphocyte subsets in relapsing-remitting multiple sclerosis: a longitudinal study of B lymphocytes and T lymphocytes", Neurol. Res. 16, 385–388.
   PubMed Web of Science ®Google Scholar
• Hohlfeld, R. and Wekerle, H. (2001) "Immunological update on multiple sclerosis", Curr. Opin. Neurol. 14, 299–304.
   PubMed Web of Science ®Google Scholar
• Gran, B., Hemmer, B., Vergelli, M., McFarland, H.F. and Martin, R. (1999) "Molecular mimicry and multiple sclerosis: degenerate T-cell recognition and the induction of autoimmunity", Ann. Neurol. 45, 559–567.
   PubMedGoogle Scholar
• Wucherpfennig, K.W. (2001) "Structural basis of molecular mimicry", J. Autoimmun. 16, 293–302.
   PubMed Web of Science ®Google Scholar
• Arnason, B.G.W. (1996) "Interferon 13 in multiple sclerosis", Clin. Immunol. ImmunopathoL 81, 1–11.
   PubMedGoogle Scholar
• Poser, C.M., Paty, D.W., Scheinberg, L., McDonald, WI., Davis, F.A., Ebers, G.C., Johnson, K.P., Sibley, W.A., Silberberg, D.H. and Tourtellotte, W.W. (1983) "New diagnostic criteria for multiple sclerosis: guidelines for research protocols", Ann. Neurol. 13, 227–231.
   PubMed Web of Science ®Google Scholar
• Kurtzke, J.F. (1983) "Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)", Neurology 33, 1444–1452.
   PubMed Web of Science ®Google Scholar
• Zettl, U.K., Mix, E., Gold, R., Rothe, G. and Hartung, H.-P. (1996) "Detection of oxidative burst and apoptotic cell death in cerebrospinal fluid (CSF) and blood", J. Lab. Med. 20, 176–177.
   Google Scholar
• Gold, R., Schmied, M., Giegerich, G., Breitschopf, H., Hartung, R-P., Toyka, K.V. and Lassmann, H. (1994) "Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques", Lab. Investig. 71, 219–225.
   PubMedGoogle Scholar
• Taniguchi, T. and Takaoka, A. (2001) "A weak signal for strong responses: interferon-a/13 revisited", Nat. Rev. Mol. Biol. 2, 378–386.
   PubMed Web of Science ®Google Scholar
• Martin, R., Stiirzebecher, C.S. and McFarland, H.F. (2001) "Immunotherapy of multiple sclerosis: where are we? Where should we go?", Nat. Immunol. 2, 785–788.
   PubMedGoogle Scholar
• Zipp, F., Beyer, M., Gelderblom, H., Wernet, D., Zschenderlein, R. and Weller, M. (2000) "No induction of apoptosis by IFN-13 in human antigen-specific T cells", Neurology 54, 485–487.
   PubMed Web of Science ®Google Scholar
• Lucas, M., Sánchez-Solirio, 0., Solano, F. and Izquferdo, G. (1998) "Interferon 13-lb inhibits reactive oxygen species production in peripheral blood monocytes of patients with relapsing-remitting multiple sclerosis", Neurochem. Int. 33, 101–102.
   PubMedGoogle Scholar
• Lucchinetti, C., Bruck, W. and Noseworthy, J. (2001) "Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment", Curr. Opin. Neurol. 14, 259–269.
   PubMed Web of Science ®Google Scholar
• Perry, V.H. (1998) "A revised view of the central nervous system microenvironment and major histocompatibility complex class 11 antigen presentation", J. Neuroimmunol. 90, 113–121.
   PubMed Web of Science ®Google Scholar
• Hartung, RP., Hughes, R.A., Taylor, WA., Heininger, K., Reiners, K. and Toyka, K.V. (1990) "T cell activation in Guillain-Barre syndrome and in MS: elevated serum levels of soluble IL-2 receptors", Neurology 40, 215–218.
   PubMed Web of Science ®Google Scholar
• Stiiber, A., Martin, R., Stone, L.A., Maloni, H. and McFarland, H.F. (1996) "Expression pattern of activation and adhesion molecules on peripheral blood CD4+ T-lymphocytes in relapsing-remitting multiple sclerosis patients: a serial analysis", J. NeuroimmunoL 66, 147–151.
   PubMedGoogle Scholar
• Mirowska, D., NZ, A., Zaborski, J., Korlak, J., Koronkiewicz, M., Skierski, J., Czionkowski, A. and Czlonkowska, A. (2001) "Changes in the immunological profile of peripheral blood leukocytes in multiple sclerosis (MS) patients treated with interferon-13-1a", J. Lab. Med. 25, 157–160.
   Google Scholar
• Byskosh, P.V. and Reder, A.T. (1996) "Interferon 13-lb effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis", Mull. Scler. 1, 262–269.
   PubMedGoogle Scholar
• Rudick, R.A., Ransohoff, R.M., Peppler, R., VanderBrug Medendorp, S., Lehmann, P. and Alam, J. (1996) "Interferon-13 induces interleukin-10 expression: relevance to multiple sclerosis", Ann. Neurol. 40, 618–627.
   PubMed Web of Science ®Google Scholar
• Byrnes, A.A., McArthur, J.C. and Karp, C.L. (2002) "Interferon-13 therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production", Ann. Neurol. 51, 165–174.
   PubMed Web of Science ®Google Scholar
• Andersson, M., Khademi, M., Wallström, E. and Olssson, T. (1997) "Cytokine profile in interferon-13 treated multiple sclerosis patients: reduction of interleukin-10 mRNA expressing cells in peripheral blood", Eur. J. Neurol. 4, 567–571.
   Google Scholar
• Waubant, E., Gee, L., Bacchetti, P., Sloan, R., Cotleur, A., Rudick, R. and Goodkin, D. (2001) "Relationship between serum levels of IL-10, MRI activity and interferon 13-la therapy in patients with relapsing remitting MS", J. Neuroimmunol. 112, 139–145.
   PubMedGoogle Scholar
• Rothuizen, L.E., Buclin, T., Spertini, F., Trinchard, I., Munafo, A., Buchwalder, P.-A., Ythier, A. and Biollaz, J. (1999) "Influence of interferon 13-la dose frequency on PBMC cytokine secretion and biological effect markers", J. NeuroimmunoL 99, 131–141.
   PubMedGoogle Scholar
• Ossege, L.M., Sindern, E., Patzold, T. and Malin, J.-P. (1998) "Inamunomodulatory effects of interferon-13-lb in vivo: induction of the expression of transforming growth factor-131 and its receptor type 11", J. Neuroimmunol. 91, 73–81.
   PubMedGoogle Scholar
• Liinemann, J.D., Aktas, 0., Gniadek, P., Zschenderlein, R. and Zipp, F. (2001) "Downregulation of transforming growth factor-131a (TGF-I3 la) treated multiple sclerosis (MS) patients (Abstract)", J. Neurol. 248 (Suppl. 2), 135.
   Google Scholar
• Becher, B., Giacomini, P.S., Pelletier, D., McCrea, E., Prat, A. and Antel, J.P. (1999) "Interferon-'y secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-13 therapy", Ann. Neurol. 45, 247–250.
   PubMed Web of Science ®Google Scholar
• Furlan, R., Bergami, A., Lang, R., Brambilla, E., Franciotta, D., Martinelli, V, Comi, G., Panina, P. and Martino, G. (2000) "Interferon-13 treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-'y and interleukin-4", J. NeuroimmunoL 111, 86–92.
   PubMed Web of Science ®Google Scholar
• Limone, P., Ferrero, B., Calvelli, P., Del Rizzo, P., Rota, E., Berardi, C., Barberis, A.M., Isaia, G.C. and Durelli, L. (2002) "Hypothalamic-pituitary-adrenal axis function and cytokine pro-duction in multiple sclerosis with and without interferon-13 treatment", Acta Neurol. Scand. 105, 372–377.
   PubMedGoogle Scholar
• Pacocha, S.E., Oriente, A., Lichtenstein, L.M., Huang, S.K. and Essayan, D.M. (2000) "Interferon-13 induces selective enhancement of antigen-specific T cell responses", J. Interferon Cytokine Res. 20, 383–389.
   PubMedGoogle Scholar
• Qu, Z.X., Pliskin, N., Jensen, M.W., White, D. and Arnason, B.G. (2001) "Etretinate augments interferon 13-lb effects on suppressor cells in multiple sclerosis", Arch. Neurol. 58, 87–90.
   PubMedGoogle Scholar
• Ekerfelt, C., Ernerudh, J., Solders, G. and Vrethem, M. (1995) "CD5 expression on B cells may be an activation marker for secretion of anti-myelin antibodies in patients with polyneuropathy associated with monoclonal ganamapathy", Clin. Exp. Immunol. 101, 346–350.
   PubMedGoogle Scholar
• De Libero, G. (2000) "Tissue distribution, antigen specificity and effector functions of gamma delta T cells in human diseases", Springer Semin. Immunopathol. 22, 219–238.
   PubMedGoogle Scholar
• Shimonkevitz, R., Colburn, C., Burnham, J.A., Murray, R.S. and Kotzin, B.L. (1993) "Clonal expansion of activated 'N/8 T cells in recent-onset multiple sclerosis", Proc. Natl Acad. Sci. USA 90, 923–927.
   PubMedGoogle Scholar
• Mix, E. and Meyer-Rienecker, H. (1996) "Fetal-type lymphocytes in blood and cerebrospinal fluid (CSF) in inflammatory diseases of the central nervous system (CNS)", J. Lab. Med. 20, 166–167.
   Google Scholar
• Rodriguez, M., Miller, D.J. and Lennon, V.A. (1996) "Immunoglobulins reactive with myelin basic protein promote CNS remyelination", Neurology 46, 538–545.
   PubMed Web of Science ®Google Scholar
• Zipp, F., Weller, M., Calabresi, PA., Frank, J.A., Bash, C.N., Dichgans, J., McFarland, H.F. and Martin, R. (1998) "Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis", Ann. Neurol. 43, 116–120.
   PubMed Web of Science ®Google Scholar
• White, CA., Nguyen, KB. and Pender, M.P. (2000) "B cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis: roles of B cell CD95, CD95L and Bc1-2 expression", J. Autoimmun. 14, 195–204.
   PubMedGoogle Scholar
• Mix, E., Zettl, U.K., Zielasek, J., Hartung, H-P. and Gold, R. (1999) "Apoptosis induction by macrophage-derived reactive oxygen species in myelin-specific T cells requires cell—cell contact", J. NeuroimmunoL 95, 152–156.
   PubMedGoogle Scholar
• Leussink, V.I., Jung, S., Merschdorf, U., Toyka, K.V. and Gold, R. (2001) "High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes", Arch. Neurol. 58, 91–97.
   PubMed Web of Science ®Google Scholar